Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Seeks Autologous Indication for G-Lasta in Japan
July 25, 2023
- Pfizer’s Aplastic Anemia Med Atgam Now Available in Japan
July 25, 2023
- Tarlige Tops GP Promotion in May, Dayvigo Most Pitched for HP: Intage
July 24, 2023
- Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
July 24, 2023
- 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
- Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
- Lecanemab Shows Large Effect in Low-Tau Population: Clarity AD
July 21, 2023
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- Japan Approves Roche’s Mpox Diagnostic
July 20, 2023
- Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
- Santen Offloads Entire North American Portfolio to Visiox, Harrow
July 20, 2023
- Kissei Pulls Japan NDA for Spinocerebellar Degeneration Treatment
July 20, 2023
- Remitch OD Tablets Approved in Thailand: Toray/Meiji Pharma
July 20, 2023
- More Crestor Generics Now on Equal Footing with Originator
July 20, 2023
- Anthony Mallet Tapped as Servier Japan Chief
July 19, 2023
- Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
- Roche Group Sues Biogen over Actemra Biosimilar
July 18, 2023
- Meiji’s Stelara Biosimilar Accepted for EU Review
July 18, 2023
- Zolbetuximab Accepted for EMA Review in CLDN18.2 Gastric Cancer: Astellas
July 18, 2023
- Nichi-Iko to Discontinue 258 Products, Largest Number Yet
July 14, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…